Less renal allograft fibrosis with valganciclovir prophylaxis for cytomegalovirus compared to high-dose valacyclovir: a parallel group, open-label, randomized controlled trial

Table 4 Patient and graft survival and other secondary outcomes

Characteristic	Valganciclovir (n = 60)	Valacyclovir (n = 59)	P Value
Patient survival	59 (98)	56 (95)	0.297
Graft survival	51 (85)	54 (92)	0.287
Estimated GFR^a (mL/min/1.73 m²)	54 ± 20	52 ± 19	0.594
Urine protein-to-creatinine ratio (mg/mmol)	23 ± 49	24 ± 43	0.339
Cardiovascular events	15 (25)	14 (24)	0.985
New-onset diabetes or IFG	26 (46)	20 (38)	0.521
Malignancy	6 (10)	2 (3)	0.283

Data are number of patients (percentage) or mean ± standard deviation. GFR, glomerular filtration rate; IFG, impaired fasting glucose
^aAccording to the Modification of Diet in Renal Disease 7 formula

ISSN: 1471-2334